ArticlePsychopharmacology2018
Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.
Article in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study.Addiction biology · 2023Trial
- Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.Psychopharmacology · 2019Trial
- Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options.Pharmacology, biochemistry, and behavior · 2024Review
- Neural circuits controlling choice behavior in opioid addiction.Neuropharmacology · 2023Review
- Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys.Drug and alcohol dependence · 2023Article
- Effects of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline (Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2023Article
- Sensitivity of a fentanyl-vs.-social interaction choice procedure to environmental and pharmacological manipulations.Pharmacology, biochemistry, and behavior · 2022Article
- In response to the study "a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient's satisfaction" by Dr. Zylla and colleagues.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Effects of combined THC and heroin vapor inhalation in rats.Psychopharmacology · 2022Article
- Translational value of non-human primates in opioid research.Experimental neurology · 2021Review
- Equal response rates maintained by concurrent drug and nondrug reinforcers: a design for treatment evaluation.Behavioural pharmacology · 2020Article
- Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.Drug and alcohol dependence · 2020Article
- Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.Behavioural pharmacology · 2020Article
- Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.Drug and alcohol dependence · 2019Article
- ΔNeuropharmacology · 2019Article
- Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCannabinoid receptor agonists such as delta-9-tetrahydrocannabinol (Δ
methodsIn this study, rhesus monkeys (n = 4) responded under a choice procedure wherein responding on one lever delivered sucrose pellets and responding on the other lever delivered intravenous infusions of the mu opioid receptor agonist remifentanil (0.032-1.0 μg/kg/infusion) alone or in combination with either Δ
resultsRemifentanil dose-dependently increased choice of drug over food, whether available alone or in combination with a cannabinoid, and the potency of remifentanil was not significantly altered by coadministration with a cannabinoid. Mixtures containing the largest doses of cannabinoids decreased response rates in most subjects, confirming that behaviorally active doses were studied.
conclusionOverall, these results extend previous studies to include choice behavior and show that cannabinoids do not substantially enhance the reinforcing effects of mu opioid receptor agonists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.